

Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale

Dr Christian SUEUR, GRECC, novembre 2019.

1. ANDRADE C. : Cannabis and Neuropsychiatry 1. Benefits and risks, *Journal of Clinical Psychiatry, Psychiatrist.com*, 2016, 77, (5), e551-4.
Doi : 10.4088/JCP.16f10841
2. ANDRADE C. : Cannabis and Neuropsychiatry 2. The longitudinal Risk of Psychosis as an Adverse Outcome, *Journal of Clinical Psychiatry, Psychiatrist.com*, 2016, 77, 6.
Doi : 10.4088/JCP.16f10918
3. ARENDT M., ROSENBERG R., FOLDAGER L., PERTO G., MUNK-JORGENSEN P. : Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders : follow-up study of 535 incident cases, *British Journal of Psychiatry*, 2005, 187, 510-515.
Doi : 10.1192/bjp.187.6.510
4. BARRETT F.S., SCHLIENZ N.J., LEMBECK N., WAQAS M., VANDREY R. : « Hallucinations » Following Acute Cannabis Dosing : A case Report and Comparison to Other Hallucinogenic Drugs, *Cannabis and Cannabinoid Research*, 2018, 3, (1), 85-93.
Doi : 10.1089/can.2017.0052
5. BATALLA A., CRIPPA J.A., BUSATTO G.F., GUIMARAES F.S., ZUARDI A.W., VALVERDE O., ATAKAN Z., McGUIRE P.K., BHATTACHARYYA S., MARTIN-SANTOS R. : Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals : a Systematic Review, *Current Pharmaceutical Design*, 2014, 20, 2168-2185.
6. BATTISTELLA G., FORNARI E., ANNONI J.-M., CHTIOUI H., DAO K., FABRITIUS M., FAVRAT B., MALL J.-F., MAEDER P., GIROUD C. : Long-Term Effects of Cannabis on Brain Structure, *Neuropsychopharmacology*, 2014, 39, 2041-2048.
Doi : 10.1038/npp.2014.67
7. BENYAMINA A., KARILA L., LAFAYE G., BLECHA L. : Genetic Influences in Cannabis Use Disorder and Psychosis : Dopamine and Beyond, *Current Pharmaceutical Design*, 2016, 22, (42), 6392-6396.
Doi : 10.2174/1381612822666160831095707
8. BHATTACHARYYA S., CRIPPA J.A., ALLEN P., MARTIN-SANTOS R., BORGWARDT S., FUSAR-POLI P., RUBIA K., KAMBEITZ J., O'CARROLL C., SEAL M.L., GIAMPIETRO V., BRAMMER M., ZUARDI A.W., ATAKAN Z., McGUIRE P.K. : Induction of Psychosis by delta-9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing, *Archives of General Psychiatry*, 2012, 69, (1), 27-36.
9. BHATTACHARYYA S., EGERTON A., KIM E., ROSSO L., BARROS D.R., HAMMERS A., BRAMMER M., TURKHEIMER F.E., HOWES O.D., McGUIRE P. : Acute induction of

- anxiety in humans by delta-9-Tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptor, *Scientific Reports*, *Nature.com*, 2017, 7, 15025. Doi : 10.1038/s41598-017-14203-4
10. BLOOMFIELD M.A.P., HINDOCHA C., GREEN S.F., WALL M.B., LEES R., PETRILLI K., COSTELLO H., OGUNBIYI M.O., BOSSONG M.G., FREEMAN T.P. : The neuropsychopharmacology of cannabis : A review of human imaging studies, *Pharmacology & Therapeutics*, 2019, 195, 132-161.
Doi : 10.1016/j.pharmthera.2018.10.006
11. BOLLA K.I., BROWN K., ELDRETH D., TATE K., CADET J.L. : Dose-related neurocognitive effects of marijuana use, *Neurology*, 2002, 59, (9), 1337-1343.
12. BOSSONG M.G., van HELL H.H., SCHUBART C.D., van SAANE W., ISEGER T.A., JAGER G., van OSCH M.J.P., JANSMA J.M., KAHN R.S., BOKS M.P., RAMSEY N.F. : Acute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype, *European Neuropsychopharmacology*, 2019.
Doi : 10.1016/j.euroneuro.2019.03.010
13. BROYD S.J., van HELL H.H., BEALE C., YÜCEL M., SOLOWIJ N. : Acute and Chronic Effects of Cannabinoids on Human Cognition – A Systematic Review, *Biological Psychiatry*, 2016, 79, (7), 557-567.
Doi : 10.1016/j.biopsych.2015.12.002
14. BUADZE A., KAISER S., STOHLER R., ROESSLER W., SEIFRITZ E., LIEBRENZ M. : Patients perceptions of the cannabis-psychosis link—a systematic review, *Current Pharmaceutical Design*, 2012, 18, (32), 5105-5112.
PMID / 22716137
15. BUDNEY A.J., SOFIS M.J., BORODOVSKY J.T. : An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.
Doi : 10.1007/s00406-018-0976-1
16. BURNS J.K. : Pathways from cannabis to psychosis : a review of the evidence, *Frontiers in Psychiatry*, 2013, 4, article 128.
Doi : 10.3389/fpsyg.2013.00128
17. CARLIN A.S., TRUPIN E.W. : The Effect of Long-Term Chronic Marijuana Use on Neuropsychological Functionning, *International Journal of the Addictions*, 1977, 12, 5, 617-624.
Doi : 10.3109/10826087709022166
18. CASTLE D.J. : Cannabis and psychosis : what causes what ?, *F1000Medicine Reports*, 2013, 5, 1, 1-4.
Doi : 10.3410/M5-1
19. CHYE Y., SUO C., LORENZETTI V., BATALLA A., COUSIJN J., GOUDRIAAN A.E., MARTIN-SANTOS R., WHITTLE S., SOLOWIJ N., YÜCEL M. : Cortical surface morphology in long-term cannabis users : A multi-site MRI study, *European Neuropsychopharmacology*, 2018.
Doi : 10.1016/j.euroneuro.2018.11.1110
20. COLIZZI M., McGUIRE P., PERTWEE R.G., BHATTACHARYYA S. : Effect of cannabis on glutamate signalling in the brain : A systematic review of human and animal evidence, *Neuroscience & Biobehavioral Reviews*, 2016, 64, 359-381.
Doi : 10.1016/j.neubiorev.2016.03.010
21. COLIZZI M., McGUIRE P., GIAMPIETRO V., WILLIAMS S., BRAMMER M., BHATTACHARYYA S. : Previous cannabis exposure modulates the acute effects

- of delta-9- tetrahydrocannabinol on attentional salience and fear processing, *Experimental and Clinical Psychopharmacology*, 2018, 26, (6), 582-598.
Doi : 10.1037/pha0000221
22. COLIZZI M., McGUIRE P., GIAMPIETRO V., WILLIAMS S., BRAMMER M., BHATTACHARYYA S. : Modulation of acute effects of delta-9- tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure, *European Neuropsychopharmacology*, 2018, 28, (7), 850-862.
Doi : 10.1016/j.euroneuro.2018.04.003
23. COLIZZI M., WELTENS N., McGUIRE P., Van OUDENHOVE L., BHATTACHARYYA S. : Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans, *Brain Sciences*, 2019, 9, (4).
Doi : 10.3390/brainsci9040093
24. COLIZZI M., WELTENS N., McGUIRE P., LYTHGOE D., WILLIAMS S., Van OUDENHOVE L., BHATTACHARYYA S. : Delta-9-Tetrahydrocannabinol increases striatal glutamate levels in healthy individuals : implications for psychosis, *Molecular Psychiatry*, 2019.
Doi : 10.1038/s41380-019-0374-8
25. COOPER Z.D., HANEY M. : Actions of delta-9-tetrahydrocannabinol in cannabis, *International Review of Psychiatry*, 2009, 21, (2), 104-112.
Doi : 10.1080/09540260902782752
26. CREAN R.D., CRANE N.A., MASON B.J. : An evidence based review of acute and longterm effects of cannabis use on executive cognitive functions, *Journal of Addiction Medicine*, 2011, 5, (1), 1-8.
Doi : 10.1097/ADM.0b013e31820c23fa
27. CURRAN H.V., FREEMAN T.P., MOKRYSZ C., LEWIS D.A., MORGAN C.J.A., PARSONS L.H. : Keep off the grass ?, Cannabis, cognition and addiction, *Nature Reviews, Neuroscience*, 2016, 1-24.
Doi : 10.1038/nrn.2016.28
28. DANIELSSON A.K., LUNDIN A., AGARDH E., ALLEBECK P., FORSELL Y. : Cannabis use, depression and anxiety : A 3-year prospective population-based study, *Journal of Affective Disorders*, 2016, 193, 103-108.
Doi : 10.1016/j.jad.2015.12.045
29. De AQUINO J.P., SHERIF M., RADHAKRISHNAN R., CAHILL J.D., RANGANATHAN M., D'SOUZA D.C. : The Psychiatric Consequences of Cannabinoids, *Clinical Therapeutics*, 2018, 1-9.
Doi : 10.1016/j.clinthera.2018.03.013
30. DERVAUX A. : Consommation de cannabis et troubles psychotiques, chapitre 6, in « *Cannabis – Quels effets sur le comportement et la Santé* », "Inserm (dir.), (Rapport - Expertise collective), Paris, Les éditions Inserm, 2001, XII- 429 p., pp 117-141.
<http://hdl.handle.net/10608/171>
31. DERVAUX A. : Effets néfastes du cannabis, chapitre 8, in « *Cannabis – Quels effets sur le comportement et la Santé* », "Inserm (dir.), (Rapport - Expertise collective), Paris, Les éditions Inserm, 2001, XII- 429 p., pp 117-141.
<http://hdl.handle.net/10608/171>
32. DERVAUX A. : Cannabis : les nouvelles données cliniques, *THS Biarritz*, 9 octobre 2013.
www.aths-biarritz.com/aths_2017/wp-content/uploads/2013/11/Mercredi-PM-Plenie%CC%80re1-Dervaux.pdf

33. DERVAUX A., KREBS M.-O., LAQUEILLE X. : Les troubles cognitifs et psychiatriques liés à la consommation de cannabis, *Bulletin de l'Académie Nationale de Médecine*, 2014, 3, 559-577.
34. DERVAUX A. : Comment le cannabis peut favoriser les troubles psychotiques : conséquences, dépistage et prise en charge, *L'Information Psychiatrique*, 2019, 95, (8), 672-628.
Doi : 10.1684/ipe.2019.2012
35. DESROSIERS N.A., RAMAEKERS J.G., CHAUCHARD E., GORELICK D.A., HUESTIS M.A. : Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers, *Journal of Analytical Toxicology*, 2015, 39, 251-261.
Doi : 10.1093/jat/bkv012
36. Di FORTI M., MORRISON P.D., BUTT A., MURRAY R.M. : Cannabis use and psychiatric and cognitive disorders : the chicken or the egg ?, *Current Opinion in Psychiatry*, 2007, 20, (3), 228-34.
Doi : 10.1097/YCO.0b013e3280fa838e
37. Di FORTI M., MORGAN C., DAZZAN P., PARIANTE C., MONDELLI V., ... MURRAY R.M. : High-potency cannabis and the risk of psychosis, *The British Journal of Psychiatry*, 2009, 195, 488-491.
Doi : 10.1192/bjp.bp.109.064220
38. Di FORTI M. et al. : Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users, *Schizophrenia Bulletin*, 2014, 40, (6), 1509-1517.
39. D'SOUZA D.C., PERRY E., MacDOUGALL L., AMMERMAN Y., COOPER T., WU Y.-T., BRALEY G., GUEORGUIEVA R., KRYSTAL J.H. : The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals : Implications for Psychosis, *Neuropsychopharmacology*, 2004, 29, 1558-1572.
40. FABER G., SMID H.G.O.M., Van GOOL A.R., WUNDERINK L., van den BOSCH R.J., WIERSMA D. : Continued Cannabis Use and Outcome in First-Episode Psychosis : Data From a Randomized, Open-Label, Controlled Trial, *Journal of Clinical Psychiatry, Psychiatrist.com*, 2012, 73, (5), 632-638.
Doi : 10.4088/JCP.11m07069
41. FEENEY K.E., KAMPMAN K.M. : Adverse effects of marijuana use, *The Linacre Quarterly*, 2016, 83, (2), 174-178.
42. FERGUSSON D.M., BODEN J.M. : Cannabis use and later life outcomes, *Addiction*, 2008, 103, (6), 969-976.
Doi : 10.1111/j.1360-0443.2008.0221.x
43. FORD T.C., HAYLEY A.C., DOWNEY L.A., PARROT A.C. : Cannabis : An Overview of its Adverse Acute and Chronic Effects and their Implications, *Current Drug Abuse Reviews*, 2016, 9, 1-14.
Doi : 10.2174/1874473710666170712113042
44. GOREY C., KUHNS L., SMARAGDI E., KROON E., COUSIJN J. : Age-related differences in the impact of cannabis use on the brain and cognition : a systematic review, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.
Doi : 10.1007/s00406-019-00981-7
45. HOCH E., NIEMANN D., von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. : How effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.
Doi : 10.1007/s00406-019-00984-4

46. HSER Y.I., MOONEY L.J., HUANG D., ZHU Y., TOMKO R.L., McCLURE E., CHOU C.P., GRAY K.M. : Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life, *Journal of Substance Abuse Treatment*, 2017, 81, 53-58.
Doi : 10.1016/j.jsat.2017.07.012
47. KARILA L., ROUX P., ROLLAND B., BENYAMINA A., REYNAUD M., AUBIN H.-J., LANCON C. : Acute and Long-Term Effects of Cannabis Use : A review, *Current Pharmaceutical Design*, 2014, 20, 1-7.
Doi : 10.2174/13816128113199990620
48. KOENDERS L., COUSIJN J., VINGERHOETS W.A.M., van den BRINK W., WIERS R.W., MEIJER C.J., MACHIELSEN M.W.J., VELTMAN D.J., GOUDRIAAN A.E., de HAAN L. : Grey Matter Changes Associated with Heavy Cannabis Use : A Longitudinal sMRI Study, *PLOS One, Research Article*, 2016, 11, (5), 1-13.
Doi : 10.1371/journal.pone.0152482
49. KROON E., KUHNS L., HOCH E., COUSIJN J. : Heavy cannabis use, dependence and the brain : a clinical perspective, *Addiction*, 2019, 1-14.
Doi : 10.1111/add.14776
50. LARGE M., MULLIN K., GUPTA P., HARRIS A., NIELSEN O. : Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use, *Australian and New Zealand Journal of Psychiatry*, 2014, 48, (5), 418-432.
Doi : 10.1177/0004867414525838
51. Le BEC P.Y., FATSEAS M., DENIS C., LAVIE E., AURIACOMBE M. : Cannabis and Psychosis : search of a causal link through a critical and systematic review, *Encephale*, 2009, 35, (4), 377-385.
Doi : 10.1016/j.encep.2008.02.012
52. LEESON V.C., HARRISON I., RON M.A., BARNES T.R., JOYCE E.M. : The effects of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia, *Schizophrenia Bulletin*, 2012, 38, (4), 873-880.
Doi : 10.1093/schbul/sbq153
53. LEWEKE F. et al. : Elevated endogenous cannabinoids in schizophrenia, *Neuroreport*, 1999, 10, 1665-1669.
54. LOBERG E.-M., HELLE S., NYGARD M., OYSTEN BERLE J., KROKEN R.A., JOHNSEN E. : The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability, *Frontiers in Psychiatry*, 2014, 5, article 159.
Doi : 10.3389/fpsyg.2014.00159
55. LORENZETTI V., SOLOWIJ N., YÜCEL M. : The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users, *Biological Psychiatry*, 2016, 79:e17-e31.
Doi : 10.1016/j.biopsych.2015.11.013
56. LORENZETTI V., ALONSO-LANA S., YOUSSEF G.J., VERDEJO-GARCIA A., SUO C., COUSIJN J., TAKAJI M., YÜCEL M., SOLOWIJ N. : Adolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ?, *Current Pharmaceutical Design*, 2016, 22, 1-14.
Doi : 10.2174/138161282266160805155922
57. LORENZETTI V., CHYE Y., SILVA P., SOLOWIJ N., ROBERTS C. : Does regular cannabis use affect neuroanatomy ? An updated systematic review and meta-analysis of structural neuroimaging studies, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.
Doi : 10.1007/s00406-019-00979-1

58. LORENZETTI V., CHYE Y., SUO C., WALTERFANG M., LUBMAN D.I., TAKAJI M., WHITTLE S., VERDEJO-GARCIA A., COUSIJN J., PANTELIS C., SEAL M., FORNITO A, YÜCEL M., SOLOWIJ N.: Neuroanatomical alterations in people with high and low cannabis dependence, *Australian & New Zealand Journal of Psychiatry*, 1-8.
Doi : 10.1177/0004867419859077
59. LOWE D.J.E., SASIADEK J.D., COLES A.S., GEORGE T.P. : Cannabis and mental illness : a review, *European Archives of Psychiatry and Clinical Neuroscience*, 2018.
Doi : 10.1007/s00406-018-0970-7
60. MALLET J., RAMOZ N., Le STRAT Y., GORWOOD P., DUBERTRET C. : Heavy cannabis use prior psychosis in schizophrenia : clinical, cognitive and neurological evidences for a new endophenotype ?, *European Archives of Psychiatry and Clinical Neuroscience*, 2017.
Doi : 10.1007/s00406-017-0767-0
61. MARCONI A. et al. : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis, *Schizophrenia Bulletin*, 2016, 42, (5), 1262-1269.
Doi : 10.1093/schbul/sbw003
62. MARTINOTTI G., Di IORIO G., SEPEDE G., De BERARDIS D., De RISIO L., Di GIANNANTONIO M. : Cannabis use and psychosis : theme introduction, *Current Pharmaceutical Design*, 2012, 18, (32), 4991-4998.
63. McLOUGHLIN B.C., PUSHPA-RAJAH J.A., GILLIES D., RATHBONE J., VARIEND H., KALAKOUTI E., KYPRIANOU K. : Cannabis and schizophrenia, *Cochrane Database Systematic Review*, 2014, 14, (10), CD004837.
Doi : 10.1002/14651858.CD004837
64. MCPARTLAND J.M., DUNCAN M., Di MARZO, PERTWEE R.G. : Are cannabidiol and delta-9-tetrahydrocannabivarin negative modulators of the endocannabinoid system ? A systematic review, *British Journal of Pharmacology*, 2015, 172, 737-753.
Doi : 10.1111/bph.12944
65. MEIER M.H., CASPI A., AMBLER A. et al. : Persistant cannabis users show neuropsychological decline from *childhood* to midlife, *Proceedings of the National Academy of Sciences*, 2012, 109, 2657-2664.
66. MEIER M.H., SCHRIBER R.A., BEARDSLEE J., HANSON J., PARDINI D. : Associations between Adolescent Cannabis Use Frequency and Adult Brain Structure : A Prospective Study of Boys Followed to Adulthood, *Drug and Alcohol Dependence*, 2019.
Doi : 10.1016/j.drugalcdep.2019.05.012
67. MEIER M.H., CASPI A., DANESE A., FISHER H.L., HOUTS R., ARSENEAULT L., MOFFIT T.E. : Associations between Adolescent Cannabis Use and Neuropsychological Decline : A Longitudinal Co-Twin Control Study, *Addiction*, 2018, 113, (2), 257-265.
Doi : 10.1111/add.13946
68. MURRAY R.M., QUIGLEY H., QUATTRONE D., ENGLUND A., Di FORTI M. : TraditionalMarijuana, high-potency cannabis and synthetic cannabinoids : increasing risk for psychosis, *World Psychiatry*, 2016, 15, (3), 195-204.
69. MURRAY R.M. et al. : Cannabis-associated psychosis : Neural substrate and clinical impact, *Neuropharmacology*, 2017, 15, 124, 89-104.
70. MYLES N., NEWALLH., NIELSEN O., LARGE M. : The association between cannabis use and earlier age at onset of schizophrenia and other psychoses :

- meta-analysis of possible confounding factors, *Current Pharmaceutical Design*, 2012, 18, (32), 5055-5069.
 PMID : 22716150
71. NADER D.A., SANCHEZ Z.M. : Effects of regular cannabis use on neurocognition, brain structure, and function : a systematic review of findings in adults, *The American Journal of Drug and Alcohol Abuse*, 2018, 44, (1), 4-18.
 Doi : 10.1080/00952990.2017.1306746
72. ORTIZ-MEDINA M.B., PEREA M., TORALES J., VENTRIGLIO A., VITRANI G., AGUILAR L., RONCERO C. : Cannabis consumption and psychosis or schizophrenia development, *International Journal of Social Psychiatry*, 2018, 64, (7), 690-704.
 Doi : 10.1177/0020764018801690
73. PAROLARO D., REALINI N., VIGANO D., GUIDALI C., RUBINO T. : The endocannabinoid system and psychiatric disorders, *Experimental Neurology*, 2010, 224, 3-14.
 Doi : 10.1016/j.expneurol.2010.03.018
74. PIOMELLI D. : The molecular logic of endocannabinoid signaling, *Nature Reviews Neuroscience*, 2003, 4, 873-884.
75. POPE H.G. Jr, GRUBER A.J., HUDSON J.L., COHANE G., HUESTIS M.A., YURGELUN-TODD D. : Early-onset cannabis use and cognitive deficits : what is the nature of the association ?, *Drug & Alcohol Dependence*, 2003, 69, (3), 303-310.
76. REYNAUD M. : Cannabis et Santé, Paris, Médecine – Science, Flammarion Ed., 2004.
77. RICHARD D. : Le Cannabis et sa Consommation, Armand Colin, 2009.
78. RUBIO G., MARIN-LOZANO J., FERRE F., MARTINEZ-GRAS I., RODRIGUEZ-JIMENEZ R., SANZ J., JIMENEZ-ARRIERO M.A., CARRASCO J.L., LORA D., JURADO R., LOPEZ-TRABADA J.R., PALOMO T. : Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis, *Comprehensive Psychiatry*, 2012, 53, (8), 1063-1070.
 Doi : 10.1016/j.comppsych.2012.04.013
79. RUSZNAK K., CSEKO K., VARGA Z., CSABAÍ D., BONA A., MAYER M., KOZMA Z., HELYES Z., CZEH B. : Long-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis, *Frontiers in Pharmacology*, 2018, 9, 786.
 Doi : 10.3389/fphar.2018.00786
80. SARA G.E., BURGESSION P.M., MALHI G.S., WHITEFORD H.A., HALL W.C. : The Impact of Cannabis and Stimulant Disorders on Diagnostic Stability in Psychosis, *Journal of Clinical Psychiatry, Psychiatrist.com*, 2014, 75, (4), 349-356.
 Doi : 10.4088/JCP.13m08878
81. SATRE D.D., BORSARI B., TOMPKINS D.A., RAMO D. : Psychiatric Disorders and Comorbid Cannabis Use : When should we be concerned and what can we do about it ?, *Journal of Clinical Psychiatry, Psychiatrist.com*, 2018, 79, 6, 18ac12268, 1-3.
 Doi : 10.4088/JCP.18ac12268
82. SCHONHOFEN P., BRISTOT I.J., CRIPPA J.A., HALLAK J.E.C., ZUARDI A.W., PARSONS R.B., KLAMT F. : Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System, *CNS Drugs, Springer Nature Switzerland*, 2018, 32, (Suppl 1), 1-16.
 Doi : 10.1007/s40263-018-0550-4

83. SCHRIVASTAVA A., JOHNSTON M., TERPSTRA K., BUREAU Y. : Pathways to psychosis in cannabis abuse, *Clinical Schizophrenia & Related Psychoses*, 2015, 9, (1), 30-35.
 Doi : 10.3371/CSRP.SHJ0.030813
84. SHALIT N., REHM J., LEV-RAN S. : The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study, *Psychiatric Research*, 2019.
 Doi : 10.1016/j.psychres.2019.05.041
85. VIGANO D., GUIDALI C., PETROSINO S., REALINI N., RUBINO T., Di MARZO V., PAROLARO D. : Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia, *International Journal of Neuropsychopharmacology*, 2009, 12, 599-614.
 Doi : 10.1017/S1461145708009371
86. VOLKOW N.D., BALER R.D., COMPTON W.M., WEISS S.R.B. : Adverse Health Effects of Marijuana Use, *The New England Journal of Medicine*, 2014, 370, (23), 2219-2227.
 Doi : 10.1056/NEJMra1402309
87. VOLKOW N.D. : The biology and potential therapeutic effects of cannabidiol, *National Institute on Drug Abuse, Senate Caucus on International Narcotics Control*, June 24, 2015.
88. WALSH Z., GONZALES R., CROSBY K., THIESSEN M.S., CARROLL C., BONN-MILLER M.O. : Medical cannabis and mental health : A guided systematic review, *Clinical Psychology Review*, 2017, 51, 15-29.
 Doi : 10.1016/j.cpr.2016.10.002
89. WEILAND B.J., THAYER R.E., DEPUE B.E., SABBINENI A., BRYAN A.D., HUTCHINSON K.E. : Daily Marijuana Use Is Not Associated with Brain Morphometric Measures in Adolescents or Adults, *The Journal of Neuroscience*, 2015, 35, (4), 1505-1512.
 Doi : 10.1523/JNEUROSCI.2946-14.2015
90. WEINSTEIN A., LIVNY A., WEIZMAN A. : Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in humans : Evidence from Studies of Adult Users, *Current Pharmaceutical Design*, 2016, 22, (42), 6366-6379.
 Doi : 10.2174/138161282266160822151323
91. WILKINSON S.T., RADHAKRISHNAN R., D'SOUZA D.C. : Impact of Cannabis Use on the Development of Psychotic Disorders, *Current Addiction Reports*, 2014, 1, (2), 115-128.
 Doi : 10.1007/s40429-014-0018-7
92. ZALEVSKY A., SOLOWIJ N., YÜCEL M., LUBMAN D.I., TAKAGI M., HARDING I.H., LORENZETTI V., WANG R., SEARLE K., PANTELIS C., SEAL M. : Effect of long-term cannabis use axonal fibre connectivity, *Brain*, 2012, 135, 2245-2255.
 Doi : 10.1093/brain/aws136
93. ZIMMER L., MORGAN J.P. : Marijuana : mythes et réalités, Georg Editeur, Genève, Editions Médecine et Hygiène, 2000.